Standard

Management of epilepsy associated with tuberous sclerosis complex : Updated clinical recommendations. / Curatolo, Paolo; Nabbout, Rima; Lagae, Lieven; Aronica, Eleonora; Ferreira, Josè Carlos; Feucht, Martha; Hertzberg, Christoph; Jansen, Anna C; Jansen, Floor; Kotulska, Katarzyna; Moavero, Romina; O'Callaghan, Finbar; Papavasiliou, Antigone; Tzadok, Michal; Jóźwiak, Sergiusz.

In: European Journal of Paediatric Neurology, Vol. 22, No. 5, 09.2018, p. 738-748.

Research output: Contribution to journalScientific review

Harvard

Curatolo, P, Nabbout, R, Lagae, L, Aronica, E, Ferreira, JC, Feucht, M, Hertzberg, C, Jansen, AC, Jansen, F, Kotulska, K, Moavero, R, O'Callaghan, F, Papavasiliou, A, Tzadok, M & Jóźwiak, S 2018, 'Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations', European Journal of Paediatric Neurology, vol. 22, no. 5, pp. 738-748. https://doi.org/10.1016/j.ejpn.2018.05.006

APA

Curatolo, P., Nabbout, R., Lagae, L., Aronica, E., Ferreira, J. C., Feucht, M., ... Jóźwiak, S. (2018). Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. European Journal of Paediatric Neurology, 22(5), 738-748. https://doi.org/10.1016/j.ejpn.2018.05.006

Vancouver

Curatolo P, Nabbout R, Lagae L, Aronica E, Ferreira JC, Feucht M et al. Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. European Journal of Paediatric Neurology. 2018 Sep;22(5):738-748. https://doi.org/10.1016/j.ejpn.2018.05.006

Author

Curatolo, Paolo ; Nabbout, Rima ; Lagae, Lieven ; Aronica, Eleonora ; Ferreira, Josè Carlos ; Feucht, Martha ; Hertzberg, Christoph ; Jansen, Anna C ; Jansen, Floor ; Kotulska, Katarzyna ; Moavero, Romina ; O'Callaghan, Finbar ; Papavasiliou, Antigone ; Tzadok, Michal ; Jóźwiak, Sergiusz. / Management of epilepsy associated with tuberous sclerosis complex : Updated clinical recommendations. In: European Journal of Paediatric Neurology. 2018 ; Vol. 22, No. 5. pp. 738-748.

BibTeX

@article{8c668c9b776949a18501740e73f9c161,
title = "Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations",
abstract = "Patients with tuberous sclerosis complex (TSC) are at very high risk for developing epilepsy, and the majority experience seizure onset during the first year of life. Early targeted interventions increase the probability of seizure-freedom and may protect neurodevelopment. In 2012, clinical recommendations for the management of epilepsy in patients with TSC were published by a panel of European experts. Since that time novel studies, reports, and expert opinions in preclinical and clinical TSC-related sciences prompted the need for updated recommendations, including epileptogenesis in TSC, the potential role of predictive biomarkers, the possible benefits of presymptomatic diagnosis and preventive treatment, and new treatment options including mTOR inhibitors. A reconvened panel reviewed the current literature to answer specific questions and five panelists discussed the findings, followed by a general discussion during which all issues were debated to achieve consensus regarding recommendations. A draft manuscript based on these discussions and recommendations was then circulated several times among the panelists, who added their own comments. All the panelists/authors agreed with the final manuscript, which was then submitted for publication. The panel concluded that the need for early diagnosis of TSC-associated seizures is now established, electroencephalographic monitoring has good predictive value for epilepsy before seizure onset in TSC, and, until conclusive data from the EPISTOP trial are available, administration of vigabatrin may be considered in children with subclinical epileptiform EEG discharges. The panel also supported the role of adjunctive everolimus for TSC-associated drug-refractory seizures and emphasized the necessity of early surgical evaluation.",
keywords = "Antiepileptic drugs, Epilepsy, mTOR, Seizures, Treatment, Tuberous sclerosis complex (TSC)",
author = "Paolo Curatolo and Rima Nabbout and Lieven Lagae and Eleonora Aronica and Ferreira, {Jos{\`e} Carlos} and Martha Feucht and Christoph Hertzberg and Jansen, {Anna C} and Floor Jansen and Katarzyna Kotulska and Romina Moavero and Finbar O'Callaghan and Antigone Papavasiliou and Michal Tzadok and Sergiusz J{\'o}źwiak",
note = "Copyright {\circledC} 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.",
year = "2018",
month = "9",
doi = "10.1016/j.ejpn.2018.05.006",
language = "English",
volume = "22",
pages = "738--748",
journal = "European Journal of Paediatric Neurology",
issn = "1090-3798",
publisher = "W.B. Saunders Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Management of epilepsy associated with tuberous sclerosis complex

T2 - Updated clinical recommendations

AU - Curatolo, Paolo

AU - Nabbout, Rima

AU - Lagae, Lieven

AU - Aronica, Eleonora

AU - Ferreira, Josè Carlos

AU - Feucht, Martha

AU - Hertzberg, Christoph

AU - Jansen, Anna C

AU - Jansen, Floor

AU - Kotulska, Katarzyna

AU - Moavero, Romina

AU - O'Callaghan, Finbar

AU - Papavasiliou, Antigone

AU - Tzadok, Michal

AU - Jóźwiak, Sergiusz

N1 - Copyright © 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

PY - 2018/9

Y1 - 2018/9

N2 - Patients with tuberous sclerosis complex (TSC) are at very high risk for developing epilepsy, and the majority experience seizure onset during the first year of life. Early targeted interventions increase the probability of seizure-freedom and may protect neurodevelopment. In 2012, clinical recommendations for the management of epilepsy in patients with TSC were published by a panel of European experts. Since that time novel studies, reports, and expert opinions in preclinical and clinical TSC-related sciences prompted the need for updated recommendations, including epileptogenesis in TSC, the potential role of predictive biomarkers, the possible benefits of presymptomatic diagnosis and preventive treatment, and new treatment options including mTOR inhibitors. A reconvened panel reviewed the current literature to answer specific questions and five panelists discussed the findings, followed by a general discussion during which all issues were debated to achieve consensus regarding recommendations. A draft manuscript based on these discussions and recommendations was then circulated several times among the panelists, who added their own comments. All the panelists/authors agreed with the final manuscript, which was then submitted for publication. The panel concluded that the need for early diagnosis of TSC-associated seizures is now established, electroencephalographic monitoring has good predictive value for epilepsy before seizure onset in TSC, and, until conclusive data from the EPISTOP trial are available, administration of vigabatrin may be considered in children with subclinical epileptiform EEG discharges. The panel also supported the role of adjunctive everolimus for TSC-associated drug-refractory seizures and emphasized the necessity of early surgical evaluation.

AB - Patients with tuberous sclerosis complex (TSC) are at very high risk for developing epilepsy, and the majority experience seizure onset during the first year of life. Early targeted interventions increase the probability of seizure-freedom and may protect neurodevelopment. In 2012, clinical recommendations for the management of epilepsy in patients with TSC were published by a panel of European experts. Since that time novel studies, reports, and expert opinions in preclinical and clinical TSC-related sciences prompted the need for updated recommendations, including epileptogenesis in TSC, the potential role of predictive biomarkers, the possible benefits of presymptomatic diagnosis and preventive treatment, and new treatment options including mTOR inhibitors. A reconvened panel reviewed the current literature to answer specific questions and five panelists discussed the findings, followed by a general discussion during which all issues were debated to achieve consensus regarding recommendations. A draft manuscript based on these discussions and recommendations was then circulated several times among the panelists, who added their own comments. All the panelists/authors agreed with the final manuscript, which was then submitted for publication. The panel concluded that the need for early diagnosis of TSC-associated seizures is now established, electroencephalographic monitoring has good predictive value for epilepsy before seizure onset in TSC, and, until conclusive data from the EPISTOP trial are available, administration of vigabatrin may be considered in children with subclinical epileptiform EEG discharges. The panel also supported the role of adjunctive everolimus for TSC-associated drug-refractory seizures and emphasized the necessity of early surgical evaluation.

KW - Antiepileptic drugs

KW - Epilepsy

KW - mTOR

KW - Seizures

KW - Treatment

KW - Tuberous sclerosis complex (TSC)

UR - http://www.scopus.com/inward/record.url?scp=85048523400&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2018.05.006

DO - 10.1016/j.ejpn.2018.05.006

M3 - Scientific review

C2 - 29880258

VL - 22

SP - 738

EP - 748

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 5

ER -

ID: 39205643